Phase 2 N=36 AMG 386 and Abiraterone for Advanced Prostate Cancer
Prostatic Neoplasms · Prostate Cancer · Neoplasm, Prostate
Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Prostatic Neoplasms
Primary: Progression Free Survival (PFS) of Cabozantinib + Docetaxel + Prednisone Compared to Docetaxel + Prednisone Alone — 8; 13; 6; 10 months
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
N/A N=20 Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline
Phase 2 N=30 Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg
Phase 2 N=59 AZD2171 to Treat Prostate Cancer
Prostate Cancer
Primary: Percent Probability of Participants With 6-month Progression-free Survival (PFS) — 43.9 percent probability
Phase 2 N=180 EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
Prostate Cancer Metastatic
Primary: Progression Free Survival (PFS) Time — 3.3; 3.4; 4.3 months
Phase 2 N=74 Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Prostate Cancer · Prostate Neoplasms · Neoplasms, Prostatic
Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 2 N=44 Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Primary: Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) — 6.8 percentage of participants
Phase 2 N=73 Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
Prostatic Neoplasms
Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants
Phase 2 N=10 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Phase 2 N=112 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Prostate Adenocarcinoma · Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Number of Participants Progression-free at 18 Months — 0 participants
Phase 3 N=1,038 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Metastatic Cancer · Prostate Cancer
Primary: Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone…
Phase 2 N=36 Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…
Phase 2 N=71 Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Prostate Cancer · Neoplasm Metastasis
Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants
Phase 2 N=62 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival — 16.1 months
Phase 3 N=1,279 S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 81.1; 70.2 months — p=.080
Phase 2 N=37 Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients With Undetectable PSA (Prostate-Specific Antigen) at 1 Year — 54.54 percentage of participants
Phase 2 N=49 Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: Best Overall PSA Response — 8; 20; 65 percentage of participatns
Phase 2 N=41 S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
Prostate Cancer
Primary: Number of Patients With Undetectable PSA — 5 Participants
Phase 3 N=1,195 Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Prostatic Neoplasms
Primary: Overall Survival — 450.0; 332.0 Days — p=<0.0001
Phase 2 N=17 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Prostate Cancer
Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants
Phase 2 N=9 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Metastatic Castration-resistant Prostate Cancer
Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants
Phase 2 N=9 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Metastatic Prostate Cancer
Primary: Recommended Phase 2 Dose (RP2D) — 25 mg
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=119 A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 29; 32; 11; 21 % of responders
Phase 2 N=41 Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data
Phase 2 N=42 Enzalutamide in Patients With High-risk Prostate Cancer
Adenocarcinoma of the Prostate
Primary: To Evaluate the Clinical Efficacy of Enzalutamide — 31 months
Phase 2 N=7 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Overall Response Rate (ORR) — 50 percentage of participants